News

Poor accrual halts one in five cancer clinical trials


 

AT THE GENITOURINARY CANCERS SYMPOSIUM

Trials were more likely to fail completion if they were funded by industry as compared with the federal government (hazard ratio, 1.97), were phase II as compared with phase III (HR, 1.29), or were single center as compared with multicenter (HR, 1.93).

On the other hand, trials were less likely to fail completion if they were conducted solely outside the United States (HR, 0.65) or both in and outside the United States (HR, 0.67), as compared with solely in the United States.

Dr. Galsky disclosed no relevant conflicts of interest.

Pages

Recommended Reading

IUDs May Protect Against Cervical Cancer
MDedge Dermatology
HPV Vaccine Safe, Effective in Girls with JIA
MDedge Dermatology
HPV Vaccine Protects Against Anal Intraepithelial Neoplasia in Gay Men
MDedge Dermatology
Labs Find Evidence of Cancer Stem Cells
MDedge Dermatology
HPV Vaccine's Benefits Are Mainly Extracervical
MDedge Dermatology
Psoriasis Patients Have Low Rates of Common Cancers
MDedge Dermatology
Baldness, prostate cancer linked among black men
MDedge Dermatology